Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 2/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156326 | 1.00 | KDM4E (0.56) | KDM4EPKMSTSGPR119USP30 | |
| SCHEMBL21848120 | 1.00 | KDM4E (0.56) | KDM4EPKMSTSGPR119USP30 | |
| SCHEMBL3325048 | 0.92 | ALDH1A1 (0.58) | KDM4EPKMGPR119USP30MEN1 | |
| SCHEMBL969044 | 0.92 | ALDH1A1 (0.58) | KDM4EPKMGPR119USP30MEN1 | |
| SCHEMBL969043 | 0.92 | ALDH1A1 (0.58) | KDM4EPKMGPR119USP30MEN1 | |
| SCHEMBL441012 | 0.92 | KDM4E (0.62) | KDM4EPKMSTSGPR119MEN1 | |
| SCHEMBL2882463 | 0.89 | KDM4E (0.51) | KDM4EPKMSTSGPR119USP30 | |
| SCHEMBL1991537 | 0.87 | KMT2A (0.52) | STSGPR119USP30MEN1KMT2A | |
| SCHEMBL29537844 | 0.87 | KMT2A (0.52) | STSGPR119USP30MEN1KMT2A | |
| SCHEMBL1991541 | 0.87 | KMT2A (0.52) | STSGPR119USP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | KDM4E 1755/4885PKM 2097/4885STS 3828/4885 |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | KDM4E 667/4885PKM 394/4885STS 787/4885 |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | KDM4E 667/4885PKM 394/4885STS 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.